{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:54:07Z","timestamp":1778860447832,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.euo.2023.05.001","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:42:04Z","timestamp":1685032924000},"page":"467-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quality of Life with Monoclonal Antibody Therapies for Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0387-2261","authenticated-orcid":false,"given":"Soufyan","family":"Annakib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Fiteni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.05.001_b0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clgc.2017.11.002","article-title":"Anti\u2013programmed cell death 1\/ligand 1 (PD-1\/PD-L1) antibodies for the treatment of urothelial carcinoma: state of the art and future development","volume":"16","author":"Powles","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2023.05.001_b0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.05.001_b0015","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2023.05.001_b0025","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.05.001_b0030","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.05.001_b0035","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0140-6736(17)32365-6","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","volume":"390","author":"Petrylak","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2023.05.001_b0040","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1200\/JCO.2003.04.166","article-title":"Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer","volume":"21","author":"Roychowdhury","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12955-018-1077-6","article-title":"Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature","volume":"17","author":"Taarnh\u00f8j","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euo.2023.05.001_b0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.05.001_b0060","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-Related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2023.05.001_b0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2018.36.5_suppl.134","article-title":"Patient-reported outcomes in PD-1\/PD-L1 inhibitor registration trials: FDA analysis of data submitted and future directions","volume":"36","author":"Howie","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0070","doi-asserted-by":"crossref","unstructured":"Fayers PM, Hays RD, editors. Assessing quality of life in clinical trials: methods and practice. ed. 2. Oxford, UK: Oxford University Press; 2004.","DOI":"10.1093\/oso\/9780198527695.001.0001"},{"key":"10.1016\/j.euo.2023.05.001_b0075","unstructured":"European Medicines Agency. Regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products \u2013 scientific guideline. London, UK: EMA; 2005. https:\/\/www.ema.europa.eu\/en\/regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products#current-effective-version-section."},{"key":"10.1016\/j.euo.2023.05.001_b0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40273-018-0752-0","article-title":"Q-TWiST analysis to assess benefit\u2013risk of pembrolizumab in patients with PD-L1\u2013positive advanced or metastatic non-small cell lung cancer","volume":"37","author":"Huang","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euo.2023.05.001_b0085","doi-asserted-by":"crossref","first-page":"11.e1","DOI":"10.1016\/j.urolonc.2021.09.012","article-title":"Evaluating health-related quality of life as a prognostic tool for overall survival in routine cancer care for older patients with bladder cancer: a US based study","volume":"40","author":"Pandit","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.euo.2023.05.001_b0095","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2023.05.001_b0100","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. GRADE Working Group; 2013. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"key":"10.1016\/j.euo.2023.05.001_b0105","unstructured":"McMaster University and Evidence Prime. GRADEpro GDT: GRADEpro guideline development tool. https:\/\/www.gradepro.org\/."},{"key":"10.1016\/j.euo.2023.05.001_b0110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.05.001_b0115","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2023.05.001_b0120","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.1016\/j.annonc.2020.08.770","volume":"31","author":"Bamias","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/cncr.32532","article-title":"Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced\/metastatic urothelial carcinoma treated with durvalumab in phase 1\/2 dose-escalation study 1108","volume":"126","author":"O\u2019Donnell","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2023.05.001_b0130","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/cam4.2958","article-title":"Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease","volume":"9","author":"Taarnh\u00f8j","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2023.05.001_b0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(19)30668-0","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial","volume":"21","author":"Petrylak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12894-020-00752-w","article-title":"Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)","volume":"20","author":"Necchi","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2023.05.001_b0145","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.eururo.2022.01.032","article-title":"Health-related quality of life of patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin after platinum and PD-1\/PD-L1 inhibitor therapy: results from cohort 1 of the phase 2 EV-201 clinical trial","volume":"81","author":"McGregor","year":"2022","journal-title":"Eur Urol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2023.05.001_b0155","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2021.39.15_suppl.4539","article-title":"Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: a randomized phase 3 trial of enfortumab vedotin versus chemotherapy","volume":"39","author":"Mamtani","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0160","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euo.2022.02.003","article-title":"Health-related quality of life with adjuvant nivolumab after radical resection for high-risk muscle-invasive urothelial carcinoma: results from the phase 3 CheckMate 274 trial","volume":"5","author":"Witjes","year":"2022","journal-title":"Eur Urol Oncol. Published online"},{"key":"10.1016\/j.euo.2023.05.001_b0165","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/jcm10091852","article-title":"Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo- or immunotherapy: a real-life experience","volume":"10","author":"Taarnh\u00f8j","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2023.05.001_b0170","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2023.05.001_b0175","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s11764-016-0533-8","article-title":"Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review","volume":"10","author":"Gopalakrishna","year":"2016","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.euo.2023.05.001_b0180","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/13548506.2019.1707242","article-title":"Illness perceptions are a potential predictor of psychological distress in patients with non-muscle-invasive bladder cancer: a 12-month prospective, longitudinal, observational study","volume":"25","author":"Zhang","year":"2020","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.euo.2023.05.001_b0185","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1442-2042.2003.00657.x","article-title":"Determinants of quality of life of bladder cancer survivors five years after treatment in France","volume":"10","author":"Matsuda","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2023.05.001_b0190","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejon.2015.09.008","article-title":"Predictors for quality of life of bladder cancer patients with ileal conduit: a cross-sectional survey","volume":"21","author":"Liu","year":"2016","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.euo.2023.05.001_b0195","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.3390\/jcm10235472","article-title":"Determinants and dynamic changes of generic quality of life in human bladder cancer patients","volume":"10","author":"Tsai","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2023.05.001_b0200","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/cncr.21896","article-title":"Quality of life in long-term survivors of bladder cancer: QOL in long-term bladder CA survivors","volume":"106","author":"Allareddy","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2023.05.001_b0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-019-0557-5","article-title":"Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy","volume":"7","author":"Bergerot","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2023.05.001_b0210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2023.05.001_b0215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MOU.0000000000000893","article-title":"Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1","volume":"31","author":"Zimmermann","year":"2021","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2023.05.001_b0220","series-title":"Adaptation to changing health: response shift in quality-of-life research","first-page":"81","article-title":"Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research","author":"Schwartz","year":"2000"},{"key":"10.1016\/j.euo.2023.05.001_b0225","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","article-title":"Integrating response shift into health-related quality of life research: a theoretical model","volume":"48","author":"Sprangers","year":"1999","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.euo.2023.05.001_b0230","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:48Z","timestamp":1762876128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2588931123000846"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.05.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Life with Monoclonal Antibody Therapies for Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}